Papillary thyroid cancer medical therapy

	Papillary thyroid cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Papillary thyroid cancer from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Papillary thyroid cancer medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Papillary thyroid cancer medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Papillary thyroid cancer medical therapy
CDC on Papillary thyroid cancer medical therapy
Papillary thyroid cancer medical therapy in the news
Blogs on Papillary thyroid cancer medical therapy
Directions to Hospitals Treating Papillary thyroid cancer
Risk calculators and risk factors for Papillary thyroid cancer medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Patients with papillary thyroid cancer are treated with radioactive iodine therapy, immunotherapy, hormone therapy and targeted medical therapy.

Levothyroxine in a dosage of 2.5-3.5 mcg/kg/day is recommended for patients post thyroidectomy.